GSK-105554



Phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunization course before 6 months of age
Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed)
105554
NCT00307541
Infections, Streptococcal
Phase 3
 
Follow on studies 106623 and 112807 were conducted.
March 2015